Regeneron's COVID-19 antibody drug may be less effective against Omicron
Reuters
Published Nov 30, 2021 06:21AM ET
Updated Nov 30, 2021 12:26PM ET
By Mrinalika Roy
(Reuters) -Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna (NASDAQ:MRNA)'s top boss raised similar concerns about the company's vaccine.
Global markets tumbled after comments from Moderna's chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.
Based on its study of Omicron's individual mutations, "there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity", Regeneron (NASDAQ:REGN) said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.
The company said it was doing further study to quantify the potential impact using the variant's genetic sequence.
One of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.
"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals."
Eli Lilly (NYSE:LLY) and Co, which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.
Regeneron shares fell about 3% in morning trading, while those of Lilly shed 2.5%.
Rival Vir Biotechnology (NASDAQ:VIR) Inc said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.
The company is "working to confirm this in the lab as a matter of urgency", it added.
Gilead (NASDAQ:GILD) Inc said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron
The U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.[nL4N2SL3Y8]
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.